



**Kosmos Energy Ltd - Director/PDMR Shareholding**

06/01/26 11:57 GMT

RNS Number : 5010G  
 Kosmos Energy Limited  
 01 June 2026

Kosmos Energy Ltd (the "Company")

**PDMR Shareholding**

**NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES**

1 June 2026

The following Persons Discharging Managerial Responsibilities ("PDMRs") have had changes in their shareholdings of Common Shares in the Company:

<b>PDMR</b>	<b>Date of transaction</b>	<b>No. of shares vested</b>	<b>No. of shares granted</b>	<b>No. of shares sold or withheld</b>
Roy A. Franklin	27 May 2026	0	0	976
Roy A. Franklin	28 May 2026	0	0	43,466
Roy A. Franklin	28 May 2026	0	62,044	0
Deanna L. Goodwin	28 May 2026	0	62,044	0
Sir John Douglas Kelso Grant	27 May 2026	0	0	735
Sir John Douglas Kelso Grant	27 May 2026	0	0	43,466
Sir John Douglas Kelso Grant	28 May 2026	0	62,044	0
Maria Moraeus Hanssen	28 May 2026	0	62,044	0
Adebayo O. Ogunlesi	28 May 2026	0	62,044	0
Steven M. Sterin	27 May 2026	0	0	38,636
Steven M. Sterin	28 May 2026	0	62,044	0
J. Michael Stice	28 May 2026	0	62,044	0

The Notification of Dealing Form for each PDMR, which provides full details of the transactions outlined above, can be found below.

This notification is made in accordance with Article 19 of the EU Market Abuse Regulation.

Josh R. Marion

Senior Vice President, General Counsel and Corporate Secretary



**CONTACT:**

**Investor Relations**

Jamie Buckland

+44 203 954 2831

[jbuckland@kosmosenergy.com](mailto:jbuckland@kosmosenergy.com)

**Media Relations**

Thomas Golembeski

+1-214-445-9674

[tgolembeski@kosmosenergy.com](mailto:tgolembeski@kosmosenergy.com)



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	Roy A. Franklin
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	976 shares withheld by the Issuer to satisfy the tax withholding requirement arising from the vesting of restricted share units granted to the reporting person under the Issuer's Long Term Incentive Plan (the "Plan").
Shares granted or vested		
c)	Currency	USD
	Price	0
	Volume	0
	Total	0
Shares sold or withheld		
d)	Currency	USD
	Price	2.85
	Volume	976
	Total	2,781.60
e)	Aggregated information	
	Price	2.85
	Volume	976
	Total	2,781.60
f)	Date of the transactions	27 May 2026
g)	Place of the transaction	NYSE
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	43,466 shares sold to partially cover income tax liability from the vesting of restricted share units granted to the reporting person under the Plan.
Shares granted or vested		
c)	Currency	USD
	Price	0
	Volume	0
	Total	0
Shares sold or withheld		
d)	Currency	USD

	Price	2.73
	Volume	43,466
	Total	118,662.18
e)	Aggregated information	
	Price	2.73
	Volume	43,466
	Total	118,662.18
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000
Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	Deanna L. Goodwin
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000
Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	Sir John Douglas Kelso Grant
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	735 shares withheld by the Issuer to satisfy the tax withholding requirement arising from the vesting of restricted share units granted to the reporting person under the Issuer's Long Term Incentive Plan (the "Plan").
Shares granted or vested		
c)	Currency	USD
	Price	0
	Volume	0
	Total	0
Shares sold or withheld		
d)	Currency	USD
	Price	2.85
	Volume	735
	Total	2,094.75
e)	Aggregated information	
	Price	2.85
	Volume	735
	Total	2,094.75
f)	Date of the transactions	27 May 2026
g)	Place of the transaction	NYSE
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	43,466 shares sold to partially cover income tax liability from the vesting of restricted share units granted to the reporting person under the Plan.
Shares granted or vested		
c)	Currency	USD
	Price	0
	Volume	0
	Total	0
Shares sold or withheld		
d)	Currency	USD

	Price	2.73
	Volume	43,466
	Total	118,615.59
e)	Aggregated information	
	Price	2.73
	Volume	43,466
	Total	118,615.59
f)	Date of the transactions	27 May 2026
g)	Place of the transaction	NYSE
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000
Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	Maria Moraeus Hanssen
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000
Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	Adebayo O. Ogunlesi
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000
Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	Steven M. Sterin
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	38,636 shares sold to partially cover income tax liability from the vesting of restricted share units granted to the reporting person under the Plan.
Shares granted or vested		
c)	Currency	USD
	Price	0
	Volume	0
	Total	0
Shares sold or withheld		
d)	Currency	USD
	Price	2.73
	Volume	38,636
	Total	105,476.28
e)	Aggregated information	
	Price	2.73
	Volume	38,636
	Total	105,476.28
f)	Date of the transactions	27 May 2026
g)	Place of the transaction	NYSE
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000

Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE



<b>1.</b>	<b>Details of PDMR / person closely associated with them ("PCA")</b>	
a)	Name	J. Michael Stice
b)	Position / status	Director
c)	Initial notification / amendment	Initial notification
<b>2.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Common Shares, par value \$0.01 per share
b)	Nature of the transactions	62,044 restricted share units granted to the reporting person on May 28, 2026 under the Plan and are scheduled to vest 100% on the earlier of May 28, 2027 or the day immediately preceding the date of the Issuer's first annual shareholder meeting following the date of grant, subject to the terms of the Plan and the applicable award agreement issued thereunder.
Shares granted or vested		
c)	Currency	USD
	Price	2.74
	Volume	62,044
	Total	170,000
Shares sold or withheld		
d)	Currency	USD
	Price	0
	Volume	0
	Total	0
e)	Aggregated information	
	Price	2.74
	Volume	62,044
	Total	170,000
f)	Date of the transactions	28 May 2026
g)	Place of the transaction	NYSE

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSSMFFFEMSEIM